- Home
- UDMY vs XNCR Comparison
UDMY vs XNCR Comparison
Compare UDMY & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UDMY
- XNCR
- Stock Information
- Founded
- UDMY 2009
- XNCR 1997
- Country
- UDMY United States
- XNCR United States
- Employees
- UDMY N/A
- XNCR N/A
- Industry
- UDMY Other Consumer Services
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- UDMY Real Estate
- XNCR Health Care
- Exchange
- UDMY Nasdaq
- XNCR Nasdaq
- Market Cap
- UDMY 1.0B
- XNCR 1.1B
- IPO Year
- UDMY 2021
- XNCR 2013
- Fundamental
- Price
- UDMY $5.42
- XNCR $14.10
- Analyst Decision
- UDMY Buy
- XNCR Buy
- Analyst Count
- UDMY 10
- XNCR 11
- Target Price
- UDMY $9.67
- XNCR $24.20
- AVG Volume (30 Days)
- UDMY 2.2M
- XNCR 1.5M
- Earning Date
- UDMY 10-29-2025
- XNCR 11-06-2025
- Dividend Yield
- UDMY N/A
- XNCR N/A
- EPS Growth
- UDMY N/A
- XNCR N/A
- EPS
- UDMY N/A
- XNCR N/A
- Revenue
- UDMY $795,801,000.00
- XNCR $146,929,000.00
- Revenue This Year
- UDMY $2.58
- XNCR $22.09
- Revenue Next Year
- UDMY $4.19
- XNCR N/A
- P/E Ratio
- UDMY N/A
- XNCR N/A
- Revenue Growth
- UDMY 2.53
- XNCR N/A
- 52 Week Low
- UDMY $5.33
- XNCR $6.92
- 52 Week High
- UDMY $10.61
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- UDMY 29.38
- XNCR 56.55
- Support Level
- UDMY $5.34
- XNCR $13.30
- Resistance Level
- UDMY $5.86
- XNCR $15.50
- Average True Range (ATR)
- UDMY 0.27
- XNCR 1.08
- MACD
- UDMY -0.16
- XNCR -0.16
- Stochastic Oscillator
- UDMY 4.02
- XNCR 54.97
About UDMY Udemy Inc.
Udemy Inc operates a marketplace platform at the center of a vibrant knowledge network. The company operates under two operating and reportable segments Consumer and Enterprise, out of which the Enterprise segment derives the maximum revenue. Geographically, the company derives maximum revenue from North America. The company leverages data, technology, and insights for effective learning experiences. It helps individuals and organizations to possess effective skill acquisition and development with flexibility.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.